Scholarlink

Rationale <p>Cocaine use disorder (CUD) remains a major public health problem, particularly among individuals receiving medications for opioid use disorder (mOUD), where ongoing cocaine use is associated with poorer treatment outcomes and elevated overdose risk. N-acetylcysteine (NAC) is a promising adjunctive candidate that reduces cocaine-seeking in preclinical models and shows mixed efficacy in humans, but its functional neural mechanisms in individuals with CUD—especially within mOUD settings—remain poorly understood.</p> Objectives <p>The present study uses functional magnetic resonance imaging (fMRI) to determine whether short-term NAC administration modulates brain activity in regions associated with inhibitory control and affective processing in people with CUD receiving medications for opioid use disorder (mOUD).</p> Methods <p>In this double-blind, placebo-controlled, crossover study, 21 individuals with CUD enrolled in an mOUD program were randomized to receive NAC or placebo for 7&#xa0;days and participated in fMRI scanning on the 7th day of this period. Following a fourteen-day washout period, participants were crossed over to receive the other condition for another 7-day period. Participants received a second fMRI scan on the 7th day of this period. Participants completed a go/no-go (GNG) and emotion-regulation task (ERT) during each scan.</p> Results <p>Compared to placebo, active NAC did not significantly affect brain activity during either the GNG task or the ERT.</p> Conclusions <p>Overall, short-term NAC did not robustly modulate neural circuits supporting inhibitory control or emotion regulation in individuals with comorbid CUD and OUD receiving mOUD, consistent with prior trials reporting limited efficacy of NAC for CUD. These findings underscore the value of incorporating neuroimaging into early-phase treatment trials to evaluate target engagement in humans.</p> Trial registration <p>ClinicalTrials.gov identifier:&#xa0;NCT02994875, registered 2016–12-16.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neuroimaging as the ‘missing link’ for preclinical to clinical translation: an example using N-acetylcysteine among individuals with cocaine- and opioid-use disorders receiving methadone treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月11日

查看全文
  • Spencer Birney,
  • Annie Cheng,
  • Theresa Babuscio,
  • Stephanie Dwy,
  • Skye Orazietti,
  • Patrick D. Worhunsky,
  • Julia Shi,
  • Mehmet Sofuoglu,
  • Todd Constable,
  • Marc N. Potenza,
  • Kathleen Carroll,
  • Sarah W. Yip

摘要

Rationale

Cocaine use disorder (CUD) remains a major public health problem, particularly among individuals receiving medications for opioid use disorder (mOUD), where ongoing cocaine use is associated with poorer treatment outcomes and elevated overdose risk. N-acetylcysteine (NAC) is a promising adjunctive candidate that reduces cocaine-seeking in preclinical models and shows mixed efficacy in humans, but its functional neural mechanisms in individuals with CUD—especially within mOUD settings—remain poorly understood.

Objectives

The present study uses functional magnetic resonance imaging (fMRI) to determine whether short-term NAC administration modulates brain activity in regions associated with inhibitory control and affective processing in people with CUD receiving medications for opioid use disorder (mOUD).

Methods

In this double-blind, placebo-controlled, crossover study, 21 individuals with CUD enrolled in an mOUD program were randomized to receive NAC or placebo for 7 days and participated in fMRI scanning on the 7th day of this period. Following a fourteen-day washout period, participants were crossed over to receive the other condition for another 7-day period. Participants received a second fMRI scan on the 7th day of this period. Participants completed a go/no-go (GNG) and emotion-regulation task (ERT) during each scan.

Results

Compared to placebo, active NAC did not significantly affect brain activity during either the GNG task or the ERT.

Conclusions

Overall, short-term NAC did not robustly modulate neural circuits supporting inhibitory control or emotion regulation in individuals with comorbid CUD and OUD receiving mOUD, consistent with prior trials reporting limited efficacy of NAC for CUD. These findings underscore the value of incorporating neuroimaging into early-phase treatment trials to evaluate target engagement in humans.

Trial registration

ClinicalTrials.gov identifier: NCT02994875, registered 2016–12-16.